May 20 (Reuters) - CUREVAC NV 5CV.DE:
Q1 REVENUE EUR 900 THOUSAND
Q1 PRETAX PROFIT EUR -51.7 MILLION
Q1 EBIT EUR -54.7 MILLION
STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025
REAFFIRMING EXPECTED CASH RUNWAY INTO 2028
YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS
NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION
Source text: ID:nEQ75HTCZa
Further company coverage: 5CV.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。